Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Sun Pharma denies unit's role in Ranbaxy share run-up before deal

Published 05/05/2014, 13:48
Updated 05/05/2014, 14:16
SUN
-
RANB
-

MUMBAI (Reuters) - India's Sun Pharmaceutical Industries Ltd (NS:SUN), which is to buy rival drugmaker Ranbaxy Laboratories Ltd (NS:RANB) for $3.2 billion (1.89 billion pounds), said its unit Silverstreet Developers LLP had no role to play in the run-up in Ranbaxy shares ahead of the deal announcement in April.

Sun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.

Ranbaxy shares had risen 24 percent and trading volumes tripled in three sessions ahead of its announcement on April 7 that Sun Pharma would buy the loss-making company from Japan's Daiichi Sankyo Ltd <4568.T>.

"We hereby confirm that we had not bought any shares in the period from 1st April to 7th April," Sun Pharma said in a statement to the National Stock Exchange. "Silverstreet had previously bought these shares as a matter of investment."

Sun Pharma's acquisition of Ranbaxy was temporarily halted last week by an Indian court in Andhra Pradesh state, pending its decision on a petition demanding a probe into alleged insider trading in Ranbaxy shares.

The court also asked all the involved companies, the regulator, and the stock exchanges for details, according to an order dated April 25 posted on the court's website.

"We were not served the notice of the hearing for the AP High Court case referred to and the matter was decided ex parte," Sun said on Monday. It added that it was responding to a request for clarification from the NSE on a news item that said the Sun-Ranbaxy deal had hit a "hurdle."

The Indian market regulator said last month that it sought information from Ranbaxy and Sun Pharma on the transaction and would ask for stock exchange trading data, after it had received "multiple complaints".

(Reporting by Zeba Siddiqui in Mumbai; Editing by Anand Basu)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.